Evaluating The Safety Of Exemestane Following 2-3 Years Of Adjuvant Tamoxifen Therapy In Postmenopausal Early Breast Cancer Patients
Status: TERMINATED
Study type: OBSERVATIONAL
Conditions: Early Breast Cancer
Interventions: OTHER: Aromasin (exemestane)
Sponsor: Pfizer